🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ken Fisher’s CGEM Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+35,998 Shares
Current Position
35,998 Shares
$655,523 Value

Ken Fisher's CGEM Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 35,998 shares of Cullinan Therapeutics, Inc. (CGEM) worth $655,523, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Ken Fisher has initiated a new position in CGEM, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's Cullinan Therapeutics (CGEM) Holding Value Over Time

Track share changes against reported price movement

Quarterly Cullinan Therapeutics (CGEM) Trades by Ken Fisher

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +35,998 New Buy 35,998 $18.21

Ken Fisher's Cullinan Therapeutics Investment FAQs

Ken Fisher first purchased Cullinan Therapeutics, Inc. (CGEM) in Q2 2026, acquiring 35,998 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held Cullinan Therapeutics, Inc. (CGEM) for 1 quarters since Q2 2026.

Ken Fisher's largest addition to Cullinan Therapeutics, Inc. (CGEM) was in Q2 2026, adding 35,998 shares worth $655,523.

According to the latest 13F filing for Q2 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 35,998 shares of Cullinan Therapeutics, Inc. (CGEM), valued at approximately $655,523.

As of the Q2 2026 filing, Cullinan Therapeutics, Inc. (CGEM) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.

Ken Fisher's peak holding in Cullinan Therapeutics, Inc. (CGEM) was 35,998 shares, as reported at the end of Q2 2026.